Instrument NameNovavax IncInstrument Symbol(NVAX-Q)

Instrument ExchangeNASDAQ

U.S. stocks fell to their worst loss since Election Day as the boost that Wall Street got from last week’s victory for Donald Trump and a cut to interest rates by the Federal Reserve kept fading

The S&P 500 Index ($SPX ) (SPY ) today is down -1.17%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.72%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -2.03%. Stocks today extended Thursday’s decline, with the S&P 500 and the Dow Jones Industrials...

The S&P 500 Index ($SPX ) (SPY ) today is down -0.70%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.34%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -1.36%. Stocks today are adding to Thursday’s losses, with the S&P 500, the Dow Jones...

December S&P 500 E-Mini futures (ESZ24) are trending down -0.19% this morning as investors held back from making big bets ahead of a crucial U.S. inflation report that could influence the Federal Reserve’s interest rate path.

Global Markets North American Markets Canada’s TSX rose on the back of global market momentum as news broke that Donald Trump had reclaimed the U.S. presidency. Investor sentiment was buoyed by expectations of pro-business policies, with the S&P 500 and Dow futures surging to record highs. This optimism in the...

Knowing these will help you avoid making suboptimal investing decisions.

Let's look beyond this piece of bad news from regulators.

Novavax stock fell 20% in one trading session on the news.

The biotech continues to earn important wins, but is it enough?

Regulators recently approved an updated COVID shot from Novavax.

Don't be too quick to jump on the Wall Street bandwagon.

Novavax Inc (NVAX) recently released its quarterly earnings report for the period ending June 30, 2024. As a key player in the biotechnology sector, Novavax’s performance and management analysis are critical for stakeholders and investors.  Key Insights from Novavax’s Q2 Reports:  Below are the key findings from the Novavax’s Q2...

Its been a good year so far for the biotech, but how long can it keep the momentum going?

/CNW/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, announced that it has filed for...

We will know a lot more about the vaccine maker's long-term prospects in 12 months.

Even if you can see it coming, you’re never going to time it just right

Shares of the vaccine maker are trading up 230% this year.

Shares of Novavax (NVAX: NSD) plummeted as the initial wave of panic surrounding COVID-19 subsided. Investors rushed to buy stocks of companies that delivered lifesaving vaccines early in the pandemic. However, Novavax's vaccine candidate was delayed, causing its stock price to tumble.   Novavax Stock: A Second Wind in a New...

These pharma and biotech players could become long-term winners.

A bird flu outbreak could spur demand for vaccines from these key players, but is it likely?

Both biotechs have been struggling for a while, but there might be some hope for them.

The vaccine maker's recovery story is looking brighter.

The biotech still hasn't lost momentum.

Can Novavax's stock continue soaring?